Roche: 2019 EPS up 13%
(CercleFinance.com) - Roche has reported EPS relative to basic activities that is up 13% (at constant exchange rates), at 20.
16 Swiss francs, with its board of directors proposing to increase its dividend to nine Swiss francs per share.
At nearly 61.5 billion francs, the group's sales increased by 9% at constant exchange rates and by 8% as reported, driven by new products, whose sales more than offset the impact of competition from biosimilars.
Roche's CEO Severin Schwan said, "For 2020 we expect sales growth in the low- to mid-single digit range in spite of the even greater impact of the competition from biosimilars."
Copyright (c) 2020 CercleFinance.com. All rights reserved.
16 Swiss francs, with its board of directors proposing to increase its dividend to nine Swiss francs per share.
At nearly 61.5 billion francs, the group's sales increased by 9% at constant exchange rates and by 8% as reported, driven by new products, whose sales more than offset the impact of competition from biosimilars.
Roche's CEO Severin Schwan said, "For 2020 we expect sales growth in the low- to mid-single digit range in spite of the even greater impact of the competition from biosimilars."
Copyright (c) 2020 CercleFinance.com. All rights reserved.